menu
Treatment resistant depression Market Insight, Epidemiology And Market Forecast 2032
Treatment resistant depression Market Insight, Epidemiology And Market Forecast 2032
Treatment resistant depression Market Insight, Epidemiology And Market Forecast 2032

Treatment-resistant depression (TRD) typically refers to inadequate response to at least one antidepressant trial of adequate doses and duration. Treatment-resistant depression is a relatively common occurrence in clinical practice, with up to 50–60% of the patients not achieving adequate response following antidepressant treatment.

Treatment-Resistant Depression Epidemiology Segmentation in the 7MM 

  • Total Diagnosed Prevalent Cases Treatment-Resistant Depression
  • Age-Specific Cases of Treatment-Resistant Depression
  • Gender-specific Cases of Treatment-Resistant Depression

Treatment-Resistant Depression Epidemiological Insights Observed in the 7MM (2021)

  • The total prevalent cases of Treatment-Resistant Depression in the 7MM were estimated to be 5.8 million.
  • The total prevalent cases of Treatment-Resistant Depression in the US were estimated to be 3.9 million.
  • The total prevalent cases of Treatment-Resistant Depression in Germany was found to be 558k and in Italy, they were found to be 127k in the year 2021.

Treatment-Resistant Depression Market Insight

The market size of Treatment-Resistant Depression in the 7MM was found to be USD 2,450 million in 2021. 

Treatment-Resistant Depression Emerging Therapies

The emerging drugs in the Treatment-Resistant Depression market are

  • AXS-05
  • VRAYLAR
  • Esketamine DPI
  • REL-1017
  • COMP360
  • MIJ821
  • Liafensine
  • MK-1942
  • NV5138
  • TS161
  • AV-101, and many others

Treatment-Resistant Depression Companies

The key players working in the Treatment-Resistant Depression market are

  • Axsome Therapeutics
  • AbbVie
  • Celon Pharma
  • Relmada Therapeutics
  • COMPASS Pathways
  • Novartis
  • Denovo Biopharma
  • Merck Sharp and Dohme Corp
  • Navitor Pharmaceuticals, Inc.
  • Supernus Pharmaceuticals, Inc.
  • Taisho Pharmaceutical Co., Ltd
  • VistaGen Therapeutics, and several others

Related Topics

Treatment resistant depression

Treatment resistant depression Market

Treatment resistant depression infographic

Treatment resistant depression Market Infographic